The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

Akyildiz, Arif; Guven, Deniz Can; Ozluk, Ahmet Anil; Ismayilov, Rashad; Mutlu, Emel; Unal, Olcun Umit; Yildiz, Ibrahim; Iriagac, Yakup; Turhal, Serdar; Akbas, Sinem; Bayram, Ertugrul; Telli, Tugba Akin; Turkoz, Fatma Paksoy; Ozcelik, Melike; Erciyestepe, Mert; Selvi, Oguzhan; Gulbagci, Burcu; Erturk, Ismail; Isleyen, Zehra Sucuoglu; Kahraman, Seda; Akdag, Mutianur Ozkorkmaz; Hamitoglu, Buket; Unek, Ilkay Tugba; Unal, Caglar; Hacibekiroglu, Ilhan; Arslan, Cagatay; Azizy, Abdulmunir; Helvaci, Kaan; Demirci, Umut; Dizdar, Omer; Basaran, Mert; Goker, Erdem; Sendur, Mehmet Ali; Yalcin, Suayib

doi:10.1097/MD.0000000000035950

The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

Files

The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular.pdf (822.51 KB)

Date

2023

Authors

dc.identifier.doi

10.1097/MD.0000000000035950

dc.identifier.other

WOS:001103423000055

Publisher

LIPPINCOTT WILLIAMS \& WILKINS

DOI

10.1097/MD.0000000000035950

Keywords

atezolizumab , bevacizumab , hepatocellular carcinoma , immunotherapy

URI

https://openaccess.acibadem.edu.tr/handle/11443/6108

Collections

WOS

Full item page

The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

Files

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By